Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Levetiracetam

An antiepileptic approved in the United States in 1999, used alone or in combination for focal, myoclonic and generalised tonic-clonic seizures; it works by binding the synaptic vesicle protein SV2A. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It was synthesised in 1977 within the piracetam family, in the search for a memory drug: it failed in that role but proved surprisingly effective against seizures in an animal model.

LevetiracetamGo to the active ingredient →
LevetiracetamActive ingredientLevetiracetamCat. No. P-L043-001CAS 102767-28-2
2-PyridonePharmacopoeial impurity2-PyridoneCat. No. P-L043-002CAS 142-08-5

EDQM standards 6

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.